Verrica Pharmaceuticals Inc.
VRCAHealthcare|Biotechnology|US
$3.19
+0.10 (+3.24%)
Tangible Book / Share
$0.20
Cash / Share
$0.53
Clinical Trials (10)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT07457918 Long-Term Follow-up Study of Cantharidin (YCANTH [VP-102/TO-208]) in Patients With Common Warts (Verruca Vulgaris) | Common Warts (Verruca Vulgaris), Common Warts | P3 | Recruiting | 250 | Open-label | — |
| NCT07246590 Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-2) | Common Warts, Common Warts (Verruca Vulgaris) | P3 | Active | 302 | RCT, Double-blind | — |
| NCT07637734 Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-3) | Common Warts, Common Warts (Verruca Vulgaris) | P3 | Recruiting | 300 | RCT, Double-blind | — |
| NCT03377803 Cantharidin Application in Molluscum Patients | Molluscum Contagiosum | P3 | Completed | 262 | RCT, Double-blind | — |
| NCT03377790 Cantharidin Application in Molluscum Patients-1 | Molluscum Contagiosum | P3 | Completed | 266 | RCT, Double-blind | — |
| NCT03186378 Evaluation of Systemic Exposure to VP-102 in Subjects With Molluscum Contagiosum. | Molluscum Contagiosum | P2 | Completed | 33 | Open-label | — |
| NCT03981822 A Placebo-Controlled Study Using VP-102 in the Treatment of External Genital Warts | Condylomata Acuminata, Papillomavirus Infections | P2 | Completed | 105 | RCT, Double-blind | — |
| NCT05188729 Open-Label Proof of Concept Study of VP-315 in Basal Cell Carcinoma | Basal Cell Carcinoma, Skin Cancer | P2 | Completed | 92 | Open-label | Part 1: VP-315 3 Day Dosing/Week, Part 2: VP-315 3 Day Dosing/Week - Loading Dose, Part 2: VP-315 3 Day Dosing/Week - No Loading Dose, Part 2: VP-315 2 Day Dosing/Week - Split Dose, Part 2: VP-315 3 Day Dosing/Week - Split Dose |
| NCT03487549 Cantharidin and Occlusion in Verruca Epithelium | Common Wart, Warts Hand | P2 | Completed | 56 | Open-label | — |
| NCT07881952 Safety and Systemic Exposure of YCANTH (VP-102) in Subjects With Common Warts (Verruca Vulgaris) (COVE-5) | Common Warts, Common Warts (Verruca Vulgaris) | P2 | Not Yet Recruiting | 30 | Open-label | — |